E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036276 |
E.1.2 | Term | Postoperative analgesia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the analgesic efficacy of a single IV dose of Org 28611 3.0 µg/kg to placebo in patients experiencing acute postoperative pain after dental impaction surgery. |
|
E.2.2 | Secondary objectives of the trial |
1. To compare the analgesic efficacy of a single IV dose of Org 28611 3.0 µg/kg to morphine sulfate 0.12 mg/kg in patients experiencing acute postoperative pain after dental impaction surgery 2. To assess the safety and tolerability of Org 28611 3.0 µg/kg compared to morphine 0.12 mg/kg and to placebo 3. To characterize the pharmacokinetic (PK) profile of Org 28611 when administered to patients experiencing acute postoperative pain after dental impaction surgery.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Has at least one mandibular partial or full bony impacted third molar requiring extraction. An ipsilateral maxillary third molar may also be extracted as may any adjacent supernumerary tooth (teeth). 2. Is willing and able to understand and complete the pain evaluations 3. Is male aged 18 to 40 years (inclusive) 4. Has a body mass index (BMI) ≤ 32 kg/m2 and a body weight of at least 65 kg. 5. Is in generally good health 6. Is able to speak, read, and understand English and provide meaningful written informed consent 7. Is able to remain at the research center for the entire 24-hour trial period 8. Has an initial pain intensity score of at least 45-mm on a 100-mm VAS and moderate or severe pain on a 4-point categorical scale within 6 hours of the end of surgery (VAS as the primary parameter and the categorical as a secondary parameter) 9. Is willing to return to the research center for the post-treatment visit 5 to 9 days after surgery and complete a 30 day SAE telephone call.
|
|
E.4 | Principal exclusion criteria |
1. Has uncontrolled or clinically significant cardiovascular, respiratory, gastrointestinal, renal, hepatic, metabolic, hematological, or immunological disease 2. Has a history of seizures, a family history of seizure disorder, or psychotic illness 3. Has a known allergy or significant adverse reaction to opioids or opioid antagonists paracetamol or ibuprofen 4. Has a history of chronic opioid or cannabis use or abuse within 6 months prior to the start of this trial 5. Has a positive urine drug test at screening or prior to surgery 6. Has participated in a trial of an investigational drug or device within 30 days prior to the trial 7. Has taken any of the following drugs within 4 hours or 5 elimination half-lives (whichever is greater) prior to dosing: aspirin, acetaminophen (paracetamol), nonsteroidal anti-inflammatory drugs (NSAIDs, COX-2 inhibitors), opioids, opioid combination drugs, sedative-hypnotics, muscle relaxants, and/or sedating antihistamines 8. Has taken a long-acting analgesic (e.g., naproxen or celecoxib), central nervous system (CNS) depressant, or alcohol (in any form) within 12 hours prior to dosing 9. Has taken a monoamine oxidase (MAO) inhibitor or tricyclic antidepressant drug within 4 weeks prior to administration of trial medication 10. Has taken a selective serotonin or norepinephrine reuptake inhibitor (SSRI or SNRI) within 4 weeks prior to the start of the trial 11. Has a medical or psychiatric condition which compromises the patient’s ability to give informed consent or appropriately complete the pain assessments 12. Has an abnormal EEG at the screening 13. Has had alcohol or caffeine in any form during 24 hours before dosing 14. Has abnormal laboratory results at the screening which in the opinion of the investigator are exclusionary |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Total pain relief over the 0 – 4 hour interval (TOTPAR0-4hr). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 4 |